input_json=
{"datacite.publisher":"ark:/13030/j2mk62hb","datacite":"<?xml version=\"1.0\"?>
<resource xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" xmlns=\"http://datacite.org/schema/kernel-3\"
xsi:schemaLocation=\"http://datacite.org/schema/kernel-3 http://schema.datacite.org/meta/kernel-3/metadata.xsd\">
  <identifier identifierType=\"DOI\">10.7272/Q6154F00</identifier>
  <creators>
    <creator>
      <creatorName>Ewers, Michael</creatorName>
    </creator>
    <creator>
      <creatorName>Insel, Philip</creatorName>
    </creator>
    <creator>
      <creatorName>Jagust, William J.</creatorName>
    </creator>
    <creator>
      <creatorName>Shaw, Leslie</creatorName>
    </creator>
    <creator>
      <creatorName>Trojanowski, John Q.</creatorName>
    </creator>
    <creator>
      <creatorName>Aisen, Paul</creatorName>
    </creator>
    <creator>
      <creatorName>Petersen, Ronald C.</creatorName>
    </creator>
    <creator>
      <creatorName>Schuff, Norbert</creatorName>
    </creator>
    <creator>
      <creatorName>Weiner, Michael W.</creatorName>
    </creator>
  </creators>
  <titles>
    <title>
      CSF Biomarker and PIB-PET Derived Beta-Amyloid Signature Predicts
      Metabolic, Grey Matter and Cognitive Changes in Non-Demented Subjects
    </title>
  </titles>
  <publisher>University of California, San Francisco</publisher>
  <publicationYear>2012</publicationYear>
  <subjects>
    <subject subjectScheme=\"MeSH\" schemeURI=\"http://www.nlm.nih.gov/mesh/\">Adult</subject>
    <subject subjectScheme=\"MeSH\" schemeURI=\"http://www.nlm.nih.gov/mesh/\">Male</subject>
    <subject subjectScheme=\"MeSH\" schemeURI=\"http://www.nlm.nih.gov/mesh/\">Female</subject>
    <subject subjectScheme=\"MeSH\" schemeURI=\"http://www.nlm.nih.gov/mesh/\">Magnetic Resonance Imaging</subject>
    <subject subjectScheme=\"MeSH\" schemeURI=\"http://www.nlm.nih.gov/mesh/\">Brain</subject>
    <subject subjectScheme=\"MeSH\" schemeURI=\"http://www.nlm.nih.gov/mesh/\">Human</subject>
    <subject subjectScheme=\"MeSH\" schemeURI=\"http://www.nlm.nih.gov/mesh/\">Aged</subject>
    <subject subjectScheme=\"MeSH\" schemeURI=\"http://www.nlm.nih.gov/mesh/\">Amyloid</subject>
    <subject subjectScheme=\"MeSH\" schemeURI=\"http://www.nlm.nih.gov/mesh/\">Cerebral Spinal Fluid</subject>
    <subject subjectScheme=\"MeSH\" schemeURI=\"http://www.nlm.nih.gov/mesh/\">Positron Emission Tomography</subject>
    <subject subjectScheme=\"MeSH\" schemeURI=\"http://www.nlm.nih.gov/mesh/\">Pathology</subject>
    <subject subjectScheme=\"MeSH\" schemeURI=\"http://www.nlm.nih.gov/mesh/\">A Beta</subject>
    <subject subjectScheme=\"MeSH\" schemeURI=\"http://www.nlm.nih.gov/mesh/\">FDG-PET</subject>
    <subject subjectScheme=\"MeSH\" schemeURI=\"http://www.nlm.nih.gov/mesh/\">Glucose Metabolism</subject>
    <subject subjectScheme=\"MeSH\" schemeURI=\"http://www.nlm.nih.gov/mesh/\">Atrophy</subject>
  </subjects>
  <contributors>
    <contributor contributorType=\"ResearchGroup\">
      <contributorName>UCSF Center for Imaging of Neurodegenerative Diseases</contributorName>
    </contributor>
  </contributors>
  <dates>
    <date dateType=\"Available\">2013-08-22T17:23:03+00:00</date>
  </dates>
  <resourceType resourceTypeGeneral=\"Dataset\">application/octet-stream</resourceType>
  <relatedIdentifiers>
    <relatedIdentifier relationType=\"References\" relatedIdentifierType=\"PMID\">22038908</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI=\"https://dx.doi.org/10.5060/D8TG65\">UCSF Datashare Data Use Agreement</rights>
  </rightsList>
  <descriptions>
    <description descriptionType=\"Abstract\">
      Beta-amyloid (A\u00df is a histopathological hallmark of Alzheimer's
      disease dementia, but high levels of A\u00df in the brain can also be found in
      a substantial proportion of nondemented subjects. Here we investigated
      which 2-year rate of brain and cognitive changes are present in
      nondemented subjects with high and low A\u00df levels, as assessed with
      cerebrospinal fluid and molecular positron emission tomography (PET)-based
      biomarkers of A\u00df. In subjects with mild cognitive impairment, increased
      brain A\u00df levels were associated with significantly faster cognitive
      decline, progression of gray matter atrophy within temporal and parietal
      brain regions, and a trend for a faster decline in parietal
      Fludeoxyglucose (FDG)-PET metabolism. Changes in gray matter and FDG-PET
      mediated the association between A\u00df and cognitive decline. In contrast,
      elderly cognitively healthy controls (HC) with high A\u00df levels showed only
      a faster medial temporal lobe and precuneus volume decline compared with
      HC with low A\u00df. In conclusion, the current results suggest not only that
      both functional and volumetric brain changes are associated with high A\u00df
      years before the onset of dementia but also that HC with substantial A\u00df
      levels show higher A\u00df pathology resistance, lack other pathologies that
      condition neurotoxic effects of A\u00df, or accumulated A\u00df for a shorter time
      period.
    </description>
    <description descriptionType=\"Methods\">
      Subjects: The study included 465 subjects of which 124 were elderly
      cognitively HC subjects, 229 subjects were diagnosed with amnestic MCI and
      112 subjects had probable AD, recruited within the North American
      multicenter Alzheimer's Disease Neuroimaging Initiative (ADNI, for
      database, see www.loni.ucla.edu/ADNI). ADNI was launched in 2003 by the
      National Institute on Aging, the National Institute of Biomedical Imaging
      and Bioengineering (NIBIB), the Food and Drug Administration, private
      pharmaceutical companies, and nonprofit organizations, as a $60 million,
      5-year public-private partnership. The primary goal of ADNI has been to
      test whether serial magnetic resonance imaging (MRI), PET, other
      biological markers, and clinical and neuropsychological assessment can be
      combined to measure the progression of MCI and early Alzheimer's
      disease (AD). The initial goal of ADNI was to recruit 800 adults, ages 55
      to 90, to participate in the research\u2014approximately 200 cognitively normal
      older individuals to be followed for 3 years, 400 people with MCI to be
      followed for 3 years, and 200 people with early AD to be followed for 2
      years. For up-to-date information, see www.adni-info.org. The current
      sample was restricted to those subjects who had either a PIB-PET
      assessment or a CSF-A\u00df-1-42 measurement. Within this subset, PIB-PET was
      available in 103 subjects including 19 HC, 65 MCI, and 19 AD subjects. The
      CSF-A\u00df-1-42 concentration was assessed in a total of 116 HC, 199 MCI, and
      102 AD subjects (see Fig. 1 for further information on subjects and data
      inclusion). Within 55 subjects, both CSF Ab1--42 and PIB-PET were
      assessed. The observation interval covered 2 years, where
      neuropsychological assessment, FDG-PET scanning, and MRI acquisition was
      conducted at baseline, 6, 12, and 24 month. All collected data are freely
      accessible online to researchers (http://www.loni.ucla.edu/ADNI). General
      inclusion criteria included an age between 55 and 90 years, a modified
      Hachinski score =4, education of at least 6 grade level, and stable
      treatment of at least 4 weeks in case of treatment with permitted
      medication (for full list, see http://www.adni-info.org, Procedures
      Manual). The diagnosis of AD was made according to the NINCDS-ADRDA
      criteria (McKhann et al. 1984). Inclusion criteria for AD encompassed
      subjective memory complaint, memory impairment as assessed by an education
      adjusted score on delayed recall of a single paragraph recall from the
      Wechsler Logical Memory II Subscale as follows: 0\u20137 years of education,
      =2; for 8\u201315 years, =4; for 16 years or more, =8, a Mini Mental State Exam
      (MMSE) score between 20 and 26, and a clinical dementia rating (CDR) score
      of 0.5 or 1. For the diagnosis of amnestic MCI, the subjects had to show
      subjective memory impairment and objective memory impairment identical to
      that for AD, a CDR of 0.5 including the memory box score of 0.5 or
      greater, and a MMSE score between 24 and 30, with unimpaired general
      cognitive ability and functional performance such that they did not meet
      criteria for dementia. HC had to show normal performance on the Logical
      Memory II Subscale adjusted for education as follows: 0\u20137 years, =3, 8\u201315
      years, =5; 16 or more years, =9, and absence of significant impairment on
      cognitive function or activities of daily living (Ewers et al. 2010). CSF
      Measurement: All CSF samples collected at the different centers were
      shipped on dry ice to the Penn ADNI Biomarker Core Laboratory at the
      University of Pennsylvania, Philadelphia, for storage at -80\u00b0C until
      further analysis at the laboratory. More details on data collection of the
      CSF samples can be found at http://www.adni-info.org, under \"ADNI
      study procedures.\" The CSF concentration of A\u00df-1-42, t-tau, and
      p-tau181 were measured in the baseline CSF samples using the multiplex
      xMAP Luminex platform (Lumnix Corp, Austin, TX) at the Penn ADNI Biomarker
      Core Laboratory. For detailed description, see Shaw et al. (2009).
      PIB-PET, FDG-PET, MRI Acquisition, and ROI Measurement: All MRI data were
      acquired on 1.5-T MRI scanners using a volumetric T1-weighted sequences to
      map brain structures, optimized for the different scanners as indicated at
      http://www.loni.ucla.edu/ADNI/Research/Cores/index (Jack, Bernstein, et
      al. 2008). Freesurfer software version 4.5 (Dale et al. 1999; Fischl et
      al. 1999) was employed to measure longitudinal changes in regional brain
      volumes. Briefly, the image-processing pipeline using FreeSurfer consisted
      of five stages: an affine registration with Talairach space, an initial
      volumetric labeling, bias field correction, nonlinear alignment to the
      Talairach space, and a final labeling of the volume. The fully automated
      labeling of volumes is achieved by warping a population based brain atlas
      to the target brain and by maximizing an a posteriori probability of the
      labels given specific constraints. A full description of the FreeSurfer
      processing steps can be found in (Fischl et al. 2002). The procedures have
      been extensively validated. MRI-volume ROIs were selected based on the
      previous meta-analyses on MRI gray matter volume measures that were most
      predictive of AD, including the hippocampus, middle temporal gyrus,
      superior temporal gyrus, amygdala, parahippocampus, entorhinal cortex,
      inferior parietal lobe, precuneus, and thalamus (Schroeter et al. 2009).
      PET data were acquired on multiple instruments of varying resolution. PIB
      scans were collected as 4 \u00d7 5 min frames beginning 50 min after injection
      of tracer. FDG scans were collected as 6 \u00d7 5 min frames beginning 30 min
      after injection of approximately 5 mCi of tracer. Attenuation correction
      was performed either via transmission scan or computer tomography. Images
      were uploaded to the Laboratory of Neuroimaging where they were processed
      to provide standard orientation, voxel size, and resolution. FDG-PET ROIs
      were constructed based on a meta-analysis of the location of FDG-PET
      changes in the brain that are typically affected in AD as described
      previously (Jagust et al. 2009; Landau et al. 2009). FDG uptake was
      normalized to a reference region composed of the pons and cerebellum and
      measured in the target ROIs that included bilateral angular gyrus,
      posterior cingulate/precuneus, and inferior temporal cortex as described
      previously (Jagust et al. 2009). PIB-PET uptake was normalized to the
      cerebellum to generate maps of the PIB-PET score used for further
      statistical analysis. Target ROIs were drawn on a structural MRI template
      from a single 79-year-old MCI subject scanned at the University of
      Pittsburgh. This image was deemed an \"average\" older subject
      with typical atrophy and ventricular size. Each subject's PIB-PET
      score map was coregistered to the individual MRI with SPM5 that was
      normalized to the MCI template with SPM5 and permitted the transformation
      of the subject's PIB-PET to the template space. ROIs in which PIB
      uptake is known to predominate were averaged in left and right hemispheres
      and comprised of prefrontal, lateral temporal, anterior cingulate gyrus,
      parietal and posterior cingulate/precuneus. Further information is
      available at the ADNI webpage (http://www.loni.ucla.edu/ADNI/).
      Neuropsychological Tests: Global cognitive ability was assessed with the
      neuropsychological test battery Alzheimer's Disease Assessment
      Scale\u2013cognitive section (ADAS-cog) (Rosen et al. 1984). The ADAS-cog score
      is the total score on a number of tests on learning and memory, language
      production, language comprehension, constructional praxis, ideational
      praxis, and orientation (see ADNI procedures manual for details at
      http://www.adni-info.org/Scientists/ProceduresManuals.aspx). A higher
      score on ADAS-cog scores indicates lower cognitive performance. Episodic
      memory was assessed with the Rey Auditory Verbal Learning Test (RAVLT),
      using the score on the 30-min delayed recall of a list of 15 words that
      had been repeatedly presented and recalled during the learning phase of 5
      verbal presentations of the list (Rey 1964). The test score corresponds to
      the number of words recalled on the 30-min delayed test. For details on
      the administration and scoring, see the \"Procedures Manual\"
      (http://www.adni-info.org/Scientists/ProceduresManuals.aspx).
    </description>
  </descriptions>
</resource>","datacite.title":"CSF Biomarker and PIB-PET Derived Beta-Amyloid Signature Predicts Metabolic, Grey Matter and
Cognitive Changes in Non-Demented Subjects.","mrt.creator":"ucsf_datashare","datacite.creator":"Ewers, Michael; Insel, Philip;
Jagust, William J.; Shaw, Leslie; Trojanowski, John Q.; Aisen, Paul; Petersen, Ronald C.; Schuff, Norbert; Weiner, Michael
W.","erc":"who: Ewers, Michael; Insel, Philip; Jagust, William J.; Shaw, Leslie; Trojanowski, John Q.; Aisen, Paul; Petersen,
Ronald C.; Schuff, Norbert; Weiner, Michael W.
what: CSF Biomarker and PIB-PET Derived Beta-Amyloid Signature Predicts
      Metabolic, Grey Matter and Cognitive Changes in Non-Demented Subjects
when: 2012
where: ark:/b7272/q6154f00
where: doi:10.7272/Q6154F00","datacite.publicationyear":"2012","datacite.resourcetype":"Dataset"}
~~~~~~~~~~
dict_pp=
{'datacite': '<?xml version="1.0"?>
'
             '<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" '
             'xmlns="http://datacite.org/schema/kernel-3" '
             'xsi:schemaLocation="http://datacite.org/schema/kernel-3 '
             'http://schema.datacite.org/meta/kernel-3/metadata.xsd">
'
             '  <identifier '
             'identifierType="DOI">10.7272/Q6154F00</identifier>
'
             '  <creators>
'
             '    <creator>
'
             '      <creatorName>Ewers, Michael</creatorName>
'
             '    </creator>
'
             '    <creator>
'
             '      <creatorName>Insel, Philip</creatorName>
'
             '    </creator>
'
             '    <creator>
'
             '      <creatorName>Jagust, William J.</creatorName>
'
             '    </creator>
'
             '    <creator>
'
             '      <creatorName>Shaw, Leslie</creatorName>
'
             '    </creator>
'
             '    <creator>
'
             '      <creatorName>Trojanowski, John Q.</creatorName>
'
             '    </creator>
'
             '    <creator>
'
             '      <creatorName>Aisen, Paul</creatorName>
'
             '    </creator>
'
             '    <creator>
'
             '      <creatorName>Petersen, Ronald C.</creatorName>
'
             '    </creator>
'
             '    <creator>
'
             '      <creatorName>Schuff, Norbert</creatorName>
'
             '    </creator>
'
             '    <creator>
'
             '      <creatorName>Weiner, Michael W.</creatorName>
'
             '    </creator>
'
             '  </creators>
'
             '  <titles>
'
             '    <title>
'
             '      CSF Biomarker and PIB-PET Derived Beta-Amyloid Signature '
             'Predicts
'
             '      Metabolic, Grey Matter and Cognitive Changes in '
             'Non-Demented Subjects
'
             '    </title>
'
             '  </titles>
'
             '  <publisher>University of California, San '
             'Francisco</publisher>
'
             '  <publicationYear>2012</publicationYear>
'
             '  <subjects>
'
             '    <subject subjectScheme="MeSH" '
             'schemeURI="http://www.nlm.nih.gov/mesh/">Adult</subject>
'
             '    <subject subjectScheme="MeSH" '
             'schemeURI="http://www.nlm.nih.gov/mesh/">Male</subject>
'
             '    <subject subjectScheme="MeSH" '
             'schemeURI="http://www.nlm.nih.gov/mesh/">Female</subject>
'
             '    <subject subjectScheme="MeSH" '
             'schemeURI="http://www.nlm.nih.gov/mesh/">Magnetic Resonance '
             'Imaging</subject>
'
             '    <subject subjectScheme="MeSH" '
             'schemeURI="http://www.nlm.nih.gov/mesh/">Brain</subject>
'
             '    <subject subjectScheme="MeSH" '
             'schemeURI="http://www.nlm.nih.gov/mesh/">Human</subject>
'
             '    <subject subjectScheme="MeSH" '
             'schemeURI="http://www.nlm.nih.gov/mesh/">Aged</subject>
'
             '    <subject subjectScheme="MeSH" '
             'schemeURI="http://www.nlm.nih.gov/mesh/">Amyloid</subject>
'
             '    <subject subjectScheme="MeSH" '
             'schemeURI="http://www.nlm.nih.gov/mesh/">Cerebral Spinal '
             'Fluid</subject>
'
             '    <subject subjectScheme="MeSH" '
             'schemeURI="http://www.nlm.nih.gov/mesh/">Positron Emission '
             'Tomography</subject>
'
             '    <subject subjectScheme="MeSH" '
             'schemeURI="http://www.nlm.nih.gov/mesh/">Pathology</subject>
'
             '    <subject subjectScheme="MeSH" '
             'schemeURI="http://www.nlm.nih.gov/mesh/">A Beta</subject>
'
             '    <subject subjectScheme="MeSH" '
             'schemeURI="http://www.nlm.nih.gov/mesh/">FDG-PET</subject>
'
             '    <subject subjectScheme="MeSH" '
             'schemeURI="http://www.nlm.nih.gov/mesh/">Glucose '
             'Metabolism</subject>
'
             '    <subject subjectScheme="MeSH" '
             'schemeURI="http://www.nlm.nih.gov/mesh/">Atrophy</subject>
'
             '  </subjects>
'
             '  <contributors>
'
             '    <contributor contributorType="ResearchGroup">
'
             '      <contributorName>UCSF Center for Imaging of '
             'Neurodegenerative Diseases</contributorName>
'
             '    </contributor>
'
             '  </contributors>
'
             '  <dates>
'
             '    <date dateType="Available">2013-08-22T17:23:03+00:00</date>
'
             '  </dates>
'
             '  <resourceType '
             'resourceTypeGeneral="Dataset">application/octet-stream</resourceType>
'
             '  <relatedIdentifiers>
'
             '    <relatedIdentifier relationType="References" '
             'relatedIdentifierType="PMID">22038908</relatedIdentifier>
'
             '  </relatedIdentifiers>
'
             '  <rightsList>
'
             '    <rights rightsURI="https://dx.doi.org/10.5060/D8TG65">UCSF '
             'Datashare Data Use Agreement</rights>
'
             '  </rightsList>
'
             '  <descriptions>
'
             '    <description descriptionType="Abstract">
'
             '      Beta-amyloid (Aß is a histopathological hallmark of '
             "Alzheimer's
"
             '      disease dementia, but high levels of Aß in the brain can '
             'also be found in
'
             '      a substantial proportion of nondemented subjects. Here we '
             'investigated
'
             '      which 2-year rate of brain and cognitive changes are '
             'present in
'
             '      nondemented subjects with high and low Aß levels, as '
             'assessed with
'
             '      cerebrospinal fluid and molecular positron emission '
             'tomography (PET)-based
'
             '      biomarkers of Aß. In subjects with mild cognitive '
             'impairment, increased
'
             '      brain Aß levels were associated with significantly faster '
             'cognitive
'
             '      decline, progression of gray matter atrophy within '
             'temporal and parietal
'
             '      brain regions, and a trend for a faster decline in '
             'parietal
'
             '      Fludeoxyglucose (FDG)-PET metabolism. Changes in gray '
             'matter and FDG-PET
'
             '      mediated the association between Aß and cognitive decline. '
             'In contrast,
'
             '      elderly cognitively healthy controls (HC) with high Aß '
             'levels showed only
'
             '      a faster medial temporal lobe and precuneus volume decline '
             'compared with
'
             '      HC with low Aß. In conclusion, the current results suggest '
             'not only that
'
             '      both functional and volumetric brain changes are '
             'associated with high Aß
'
             '      years before the onset of dementia but also that HC with '
             'substantial Aß
'
             '      levels show higher Aß pathology resistance, lack other '
             'pathologies that
'
             '      condition neurotoxic effects of Aß, or accumulated Aß for '
             'a shorter time
'
             '      period.
'
             '    </description>
'
             '    <description descriptionType="Methods">
'
             '      Subjects: The study included 465 subjects of which 124 '
             'were elderly
'
             '      cognitively HC subjects, 229 subjects were diagnosed with '
             'amnestic MCI and
'
             '      112 subjects had probable AD, recruited within the North '
             'American
'
             "      multicenter Alzheimer's Disease Neuroimaging Initiative "
             '(ADNI, for
'
             '      database, see www.loni.ucla.edu/ADNI). ADNI was launched '
             'in 2003 by the
'
             '      National Institute on Aging, the National Institute of '
             'Biomedical Imaging
'
             '      and Bioengineering (NIBIB), the Food and Drug '
             'Administration, private
'
             '      pharmaceutical companies, and nonprofit organizations, as '
             'a $60 million,
'
             '      5-year public-private partnership. The primary goal of '
             'ADNI has been to
'
             '      test whether serial magnetic resonance imaging (MRI), PET, '
             'other
'
             '      biological markers, and clinical and neuropsychological '
             'assessment can be
'
             '      combined to measure the progression of MCI and early '
             "Alzheimer's
"
             '      disease (AD). The initial goal of ADNI was to recruit 800 '
             'adults, ages 55
'
             '      to 90, to participate in the research—approximately 200 '
             'cognitively normal
'
             '      older individuals to be followed for 3 years, 400 people '
             'with MCI to be
'
             '      followed for 3 years, and 200 people with early AD to be '
             'followed for 2
'
             '      years. For up-to-date information, see www.adni-info.org. '
             'The current
'
             '      sample was restricted to those subjects who had either a '
             'PIB-PET
'
             '      assessment or a CSF-Aß-1-42 measurement. Within this '
             'subset, PIB-PET was
'
             '      available in 103 subjects including 19 HC, 65 MCI, and 19 '
             'AD subjects. The
'
             '      CSF-Aß-1-42 concentration was assessed in a total of 116 '
             'HC, 199 MCI, and
'
             '      102 AD subjects (see Fig. 1 for further information on '
             'subjects and data
'
             '      inclusion). Within 55 subjects, both CSF Ab1--42 and '
             'PIB-PET were
'
             '      assessed. The observation interval covered 2 years, where
'
             '      neuropsychological assessment, FDG-PET scanning, and MRI '
             'acquisition was
'
             '      conducted at baseline, 6, 12, and 24 month. All collected '
             'data are freely
'
             '      accessible online to researchers '
             '(http://www.loni.ucla.edu/ADNI). General
'
             '      inclusion criteria included an age between 55 and 90 '
             'years, a modified
'
             '      Hachinski score =4, education of at least 6 grade level, '
             'and stable
'
             '      treatment of at least 4 weeks in case of treatment with '
             'permitted
'
             '      medication (for full list, see http://www.adni-info.org, '
             'Procedures
'
             '      Manual). The diagnosis of AD was made according to the '
             'NINCDS-ADRDA
'
             '      criteria (McKhann et al. 1984). Inclusion criteria for AD '
             'encompassed
'
             '      subjective memory complaint, memory impairment as assessed '
             'by an education
'
             '      adjusted score on delayed recall of a single paragraph '
             'recall from the
'
             '      Wechsler Logical Memory II Subscale as follows: 0–7 years '
             'of education,
'
             '      =2; for 8–15 years, =4; for 16 years or more, =8, a Mini '
             'Mental State Exam
'
             '      (MMSE) score between 20 and 26, and a clinical dementia '
             'rating (CDR) score
'
             '      of 0.5 or 1. For the diagnosis of amnestic MCI, the '
             'subjects had to show
'
             '      subjective memory impairment and objective memory '
             'impairment identical to
'
             '      that for AD, a CDR of 0.5 including the memory box score '
             'of 0.5 or
'
             '      greater, and a MMSE score between 24 and 30, with '
             'unimpaired general
'
             '      cognitive ability and functional performance such that '
             'they did not meet
'
             '      criteria for dementia. HC had to show normal performance '
             'on the Logical
'
             '      Memory II Subscale adjusted for education as follows: 0–7 '
             'years, =3, 8–15
'
             '      years, =5; 16 or more years, =9, and absence of '
             'significant impairment on
'
             '      cognitive function or activities of daily living (Ewers et '
             'al. 2010). CSF
'
             '      Measurement: All CSF samples collected at the different '
             'centers were
'
             '      shipped on dry ice to the Penn ADNI Biomarker Core '
             'Laboratory at the
'
             '      University of Pennsylvania, Philadelphia, for storage at '
             '-80°C until
'
             '      further analysis at the laboratory. More details on data '
             'collection of the
'
             '      CSF samples can be found at http://www.adni-info.org, '
             'under "ADNI
'
             '      study procedures." The CSF concentration of Aß-1-42, '
             't-tau, and
'
             '      p-tau181 were measured in the baseline CSF samples using '
             'the multiplex
'
             '      xMAP Luminex platform (Lumnix Corp, Austin, TX) at the '
             'Penn ADNI Biomarker
'
             '      Core Laboratory. For detailed description, see Shaw et al. '
             '(2009).
'
             '      PIB-PET, FDG-PET, MRI Acquisition, and ROI Measurement: '
             'All MRI data were
'
             '      acquired on 1.5-T MRI scanners using a volumetric '
             'T1-weighted sequences to
'
             '      map brain structures, optimized for the different scanners '
             'as indicated at
'
             '      http://www.loni.ucla.edu/ADNI/Research/Cores/index (Jack, '
             'Bernstein, et
'
             '      al. 2008). Freesurfer software version 4.5 (Dale et al. '
             '1999; Fischl et
'
             '      al. 1999) was employed to measure longitudinal changes in '
             'regional brain
'
             '      volumes. Briefly, the image-processing pipeline using '
             'FreeSurfer consisted
'
             '      of five stages: an affine registration with Talairach '
             'space, an initial
'
             '      volumetric labeling, bias field correction, nonlinear '
             'alignment to the
'
             '      Talairach space, and a final labeling of the volume. The '
             'fully automated
'
             '      labeling of volumes is achieved by warping a population '
             'based brain atlas
'
             '      to the target brain and by maximizing an a posteriori '
             'probability of the
'
             '      labels given specific constraints. A full description of '
             'the FreeSurfer
'
             '      processing steps can be found in (Fischl et al. 2002). The '
             'procedures have
'
             '      been extensively validated. MRI-volume ROIs were selected '
             'based on the
'
             '      previous meta-analyses on MRI gray matter volume measures '
             'that were most
'
             '      predictive of AD, including the hippocampus, middle '
             'temporal gyrus,
'
             '      superior temporal gyrus, amygdala, parahippocampus, '
             'entorhinal cortex,
'
             '      inferior parietal lobe, precuneus, and thalamus (Schroeter '
             'et al. 2009).
'
             '      PET data were acquired on multiple instruments of varying '
             'resolution. PIB
'
             '      scans were collected as 4 × 5 min frames beginning 50 min '
             'after injection
'
             '      of tracer. FDG scans were collected as 6 × 5 min frames '
             'beginning 30 min
'
             '      after injection of approximately 5 mCi of tracer. '
             'Attenuation correction
'
             '      was performed either via transmission scan or computer '
             'tomography. Images
'
             '      were uploaded to the Laboratory of Neuroimaging where they '
             'were processed
'
             '      to provide standard orientation, voxel size, and '
             'resolution. FDG-PET ROIs
'
             '      were constructed based on a meta-analysis of the location '
             'of FDG-PET
'
             '      changes in the brain that are typically affected in AD as '
             'described
'
             '      previously (Jagust et al. 2009; Landau et al. 2009). FDG '
             'uptake was
'
             '      normalized to a reference region composed of the pons and '
             'cerebellum and
'
             '      measured in the target ROIs that included bilateral '
             'angular gyrus,
'
             '      posterior cingulate/precuneus, and inferior temporal '
             'cortex as described
'
             '      previously (Jagust et al. 2009). PIB-PET uptake was '
             'normalized to the
'
             '      cerebellum to generate maps of the PIB-PET score used for '
             'further
'
             '      statistical analysis. Target ROIs were drawn on a '
             'structural MRI template
'
             '      from a single 79-year-old MCI subject scanned at the '
             'University of
'
             '      Pittsburgh. This image was deemed an "average" older '
             'subject
'
             "      with typical atrophy and ventricular size. Each subject's "
             'PIB-PET
'
             '      score map was coregistered to the individual MRI with SPM5 '
             'that was
'
             '      normalized to the MCI template with SPM5 and permitted the '
             'transformation
'
             "      of the subject's PIB-PET to the template space. ROIs in "
             'which PIB
'
             '      uptake is known to predominate were averaged in left and '
             'right hemispheres
'
             '      and comprised of prefrontal, lateral temporal, anterior '
             'cingulate gyrus,
'
             '      parietal and posterior cingulate/precuneus. Further '
             'information is
'
             '      available at the ADNI webpage '
             '(http://www.loni.ucla.edu/ADNI/).
'
             '      Neuropsychological Tests: Global cognitive ability was '
             'assessed with the
'
             "      neuropsychological test battery Alzheimer's Disease "
             'Assessment
'
             '      Scale–cognitive section (ADAS-cog) (Rosen et al. 1984). '
             'The ADAS-cog score
'
             '      is the total score on a number of tests on learning and '
             'memory, language
'
             '      production, language comprehension, constructional praxis, '
             'ideational
'
             '      praxis, and orientation (see ADNI procedures manual for '
             'details at
'
             '      '
             'http://www.adni-info.org/Scientists/ProceduresManuals.aspx). A '
             'higher
'
             '      score on ADAS-cog scores indicates lower cognitive '
             'performance. Episodic
'
             '      memory was assessed with the Rey Auditory Verbal Learning '
             'Test (RAVLT),
'
             '      using the score on the 30-min delayed recall of a list of '
             '15 words that
'
             '      had been repeatedly presented and recalled during the '
             'learning phase of 5
'
             '      verbal presentations of the list (Rey 1964). The test '
             'score corresponds to
'
             '      the number of words recalled on the 30-min delayed test. '
             'For details on
'
             '      the administration and scoring, see the "Procedures '
             'Manual"
'
             '      '
             '(http://www.adni-info.org/Scientists/ProceduresManuals.aspx).
'
             '    </description>
'
             '  </descriptions>
'
             '</resource>',
 'datacite.creator': 'Ewers, Michael; Insel, Philip; Jagust, William J.; Shaw, '
                     'Leslie; Trojanowski, John Q.; Aisen, Paul; Petersen, '
                     'Ronald C.; Schuff, Norbert; Weiner, Michael W.',
 'datacite.publicationyear': '2012',
 'datacite.publisher': 'ark:/13030/j2mk62hb',
 'datacite.resourcetype': 'Dataset',
 'datacite.title': 'CSF Biomarker and PIB-PET Derived Beta-Amyloid Signature '
                   'Predicts Metabolic, Grey Matter and Cognitive Changes in '
                   'Non-Demented Subjects.',
 'erc': 'who: Ewers, Michael; Insel, Philip; Jagust, William J.; Shaw, Leslie; '
        'Trojanowski, John Q.; Aisen, Paul; Petersen, Ronald C.; Schuff, '
        'Norbert; Weiner, Michael W.
'
        'what: CSF Biomarker and PIB-PET Derived Beta-Amyloid Signature '
        'Predicts
'
        '      Metabolic, Grey Matter and Cognitive Changes in Non-Demented '
        'Subjects
'
        'when: 2012
'
        'where: ark:/b7272/q6154f00
'
        'where: doi:10.7272/Q6154F00',
 'mrt.creator': 'ucsf_datashare'}
~~~~~~~~~~
keys=
datacite.publisher, datacite, datacite.title, mrt.creator, datacite.creator, erc, datacite.publicationyear, datacite.resourcetype
~~~~~~~~~~
output_exchange=
datacite.publisher ark:/13030/j2mk62hb datacite
<?xml%20version%3D%221.0%22?>%0A<resource%20xmlns:xsi%3D%22http://www.w3.org/2001/XMLSchema-
instance%22%20xmlns%3D%22http://datacite.org/schema/kernel-3%22%20xsi:schemaLocation%3D%22http://datacite.org/schema/kernel-3%20http://schema.datacite.org/meta/kernel-3/metadata.xsd%22>%0A%20%20<identifier%20identifierType%3D%22DOI%22>10.7272/Q6154F00</identifier>%0A%20%20<creators>%0A%20%20%20%20<creator>%0A%20%20%20%20%20%20<creatorName>Ewers,%20Michael</creatorName>%0A%20%20%20%20</creator>%0A%20%20%20%20<creator>%0A%20%20%20%20%20%20<creatorName>Insel,%20Philip</creatorName>%0A%20%20%20%20</creator>%0A%20%20%20%20<creator>%0A%20%20%20%20%20%20<creatorName>Jagust,%20William%20J.</creatorName>%0A%20%20%20%20</creator>%0A%20%20%20%20<creator>%0A%20%20%20%20%20%20<creatorName>Shaw,%20Leslie</creatorName>%0A%20%20%20%20</creator>%0A%20%20%20%20<creator>%0A%20%20%20%20%20%20<creatorName>Trojanowski,%20John%20Q.</creatorName>%0A%20%20%20%20</creator>%0A%20%20%20%20<creator>%0A%20%20%20%20%20%20<creatorName>Aisen,%20Paul</creatorName>%0A%20%20%20%20</creator>%0A%20%20%20%20<creator>%0A%20%20%20%20%20%20<creatorName>Petersen,%20Ronald%20C.</creatorName>%0A%20%20%20%20</creator>%0A%20%20%20%20<creator>%0A%20%20%20%20%20%20<creatorName>Schuff,%20Norbert</creatorName>%0A%20%20%20%20</creator>%0A%20%20%20%20<creator>%0A%20%20%20%20%20%20<creatorName>Weiner,%20Michael%20W.</creatorName>%0A%20%20%20%20</creator>%0A%20%20</creators>%0A%20%20<titles>%0A%20%20%20%20<title>%0A%20%20%20%20%20%20CSF%20Biomarker%20and%20PIB-
PET%20Derived%20Beta-
Amyloid%20Signature%20Predicts%0A%20%20%20%20%20%20Metabolic,%20Grey%20Matter%20and%20Cognitive%20Changes%20in%20Non-
Demented%20Subjects%0A%20%20%20%20</title>%0A%20%20</titles>%0A%20%20<publisher>University%20of%20California,%20San%20Francisco</publisher>%0A%20%20<publicationYear>2012</publicationYear>%0A%20%20<subjects>%0A%20%20%20%20<subject%20subjectScheme%3D%22MeSH%22%20schemeURI%3D%22http://www.nlm.nih.gov/mesh/%22>Adult</subject>%0A%20%20%20%20<subject%20subjectScheme%3D%22MeSH%22%20schemeURI%3D%22http://www.nlm.nih.gov/mesh/%22>Male</subject>%0A%20%20%20%20<subject%20subjectScheme%3D%22MeSH%22%20schemeURI%3D%22http://www.nlm.nih.gov/mesh/%22>Female</subject>%0A%20%20%20%20<subject%20subjectScheme%3D%22MeSH%22%20schemeURI%3D%22http://www.nlm.nih.gov/mesh/%22>Magnetic%20Resonance%20Imaging</subject>%0A%20%20%20%20<subject%20subjectScheme%3D%22MeSH%22%20schemeURI%3D%22http://www.nlm.nih.gov/mesh/%22>Brain</subject>%0A%20%20%20%20<subject%20subjectScheme%3D%22MeSH%22%20schemeURI%3D%22http://www.nlm.nih.gov/mesh/%22>Human</subject>%0A%20%20%20%20<subject%20subjectScheme%3D%22MeSH%22%20schemeURI%3D%22http://www.nlm.nih.gov/mesh/%22>Aged</subject>%0A%20%20%20%20<subject%20subjectScheme%3D%22MeSH%22%20schemeURI%3D%22http://www.nlm.nih.gov/mesh/%22>Amyloid</subject>%0A%20%20%20%20<subject%20subjectScheme%3D%22MeSH%22%20schemeURI%3D%22http://www.nlm.nih.gov/mesh/%22>Cerebral%20Spinal%20Fluid</subject>%0A%20%20%20%20<subject%20subjectScheme%3D%22MeSH%22%20schemeURI%3D%22http://www.nlm.nih.gov/mesh/%22>Positron%20Emission%20Tomography</subject>%0A%20%20%20%20<subject%20subjectScheme%3D%22MeSH%22%20schemeURI%3D%22http://www.nlm.nih.gov/mesh/%22>Pathology</subject>%0A%20%20%20%20<subject%20subjectScheme%3D%22MeSH%22%20schemeURI%3D%22http://www.nlm.nih.gov/mesh/%22>A%20Beta</subject>%0A%20%20%20%20<subject%20subjectScheme%3D%22MeSH%22%20schemeURI%3D%22http://www.nlm.nih.gov/mesh/%22>FDG-
PET</subject>%0A%20%20%20%20<subject%20subjectScheme%3D%22MeSH%22%20schemeURI%3D%22http://www.nlm.nih.gov/mesh/%22>Glucose%20Metabolism</subject>%0A%20%20%20%20<subject%20subjectScheme%3D%22MeSH%22%20schemeURI%3D%22http://www.nlm.nih.gov/mesh/%22>Atrophy</subject>%0A%20%20</subjects>%0A%20%20<contributors>%0A%20%20%20%20<contributor%20contributorType%3D%22ResearchGroup%22>%0A%20%20%20%20%20%20<contributorName>UCSF%20Center%20for%20Imaging%20of%20Neurodegenerative%20Diseases</contributorName>%0A%20%20%20%20</contributor>%0A%20%20</contributors>%0A%20%20<dates>%0A%20%20%20%20<date%20dateType%3D%22Available%22>2013-08-22T17:23:03+00:00</date>%0A%20%20</dates>%0A%20%20<resourceType%20resourceTypeGeneral%3D%22Dataset%22>application/octet-
stream</resourceType>%0A%20%20<relatedIdentifiers>%0A%20%20%20%20<relatedIdentifier%20relationType%3D%22References%22%20relatedIdentifierType%3D%22PMID%22>22038908</relatedIdentifier>%0A%20%20</relatedIdentifiers>%0A%20%20<rightsList>%0A%20%20%20%20<rights%20rightsURI%3D%22https://dx.doi.org/10.5060/D8TG65%22>UCSF%20Datashare%20Data%20Use%20Agreement</rights>%0A%20%20</rightsList>%0A%20%20<descriptions>%0A%20%20%20%20<description%20descriptionType%3D%22Abstract%22>%0A%20%20%20%20%20%20Beta-
amyloid%20%28A%DF%20is%20a%20histopathological%20hallmark%20of%20Alzheimer%27s%0A%20%20%20%20%20%20disease%20dementia,%20but%20high%20levels%20of%20A%DF%20in%20the%20brain%20can%20also%20be%20found%20in%0A%20%20%20%20%20%20a%20substantial%20proportion%20of%20nondemented%20subjects.%20Here%20we%20investigated%0A%20%20%20%20%20%20which%202-year%20rate%20of%20brain%20and%20cognitive%20changes%20are%20present%20in%0A%20%20%20%20%20%20nondemented%20subjects%20with%20high%20and%20low%20A%DF%20levels,%20as%20assessed%20with%0A%20%20%20%20%20%20cerebrospinal%20fluid%20and%20molecular%20positron%20emission%20tomography%20%28PET%29-based%0A%20%20%20%20%20%20biomarkers%20of%20A%DF.%20In%20subjects%20with%20mild%20cognitive%20impairment,%20increased%0A%20%20%20%20%20%20brain%20A%DF%20levels%20were%20associated%20with%20significantly%20faster%20cognitive%0A%20%20%20%20%20%20decline,%20progression%20of%20gray%20matter%20atrophy%20within%20temporal%20and%20parietal%0A%20%20%20%20%20%20brain%20regions,%20and%20a%20trend%20for%20a%20faster%20decline%20in%20parietal%0A%20%20%20%20%20%20Fludeoxyglucose%20%28FDG%29-PET%20metabolism.%20Changes%20in%20gray%20matter%20and%20FDG-
PET%0A%20%20%20%20%20%20mediated%20the%20association%20between%20A%DF%20and%20cognitive%20decline.%20In%20contrast,%0A%20%20%20%20%20%20elderly%20cognitively%20healthy%20controls%20%28HC%29%20with%20high%20A%DF%20levels%20showed%20only%0A%20%20%20%20%20%20a%20faster%20medial%20temporal%20lobe%20and%20precuneus%20volume%20decline%20compared%20with%0A%20%20%20%20%20%20HC%20with%20low%20A%DF.%20In%20conclusion,%20the%20current%20results%20suggest%20not%20only%20that%0A%20%20%20%20%20%20both%20functional%20and%20volumetric%20brain%20changes%20are%20associated%20with%20high%20A%DF%0A%20%20%20%20%20%20years%20before%20the%20onset%20of%20dementia%20but%20also%20that%20HC%20with%20substantial%20A%DF%0A%20%20%20%20%20%20levels%20show%20higher%20A%DF%20pathology%20resistance,%20lack%20other%20pathologies%20that%0A%20%20%20%20%20%20condition%20neurotoxic%20effects%20of%20A%DF,%20or%20accumulated%20A%DF%20for%20a%20shorter%20time%0A%20%20%20%20%20%20period.%0A%20%20%20%20</description>%0A%20%20%20%20<description%20descriptionType%3D%22Methods%22>%0A%20%20%20%20%20%20Subjects:%20The%20study%20included%20465%20subjects%20of%20which%20124%20were%20elderly%0A%20%20%20%20%20%20cognitively%20HC%20subjects,%20229%20subjects%20were%20diagnosed%20with%20amnestic%20MCI%20and%0A%20%20%20%20%20%20112%20subjects%20had%20probable%20AD,%20recruited%20within%20the%20North%20American%0A%20%20%20%20%20%20multicenter%20Alzheimer%27s%20Disease%20Neuroimaging%20Initiative%20%28ADNI,%20for%0A%20%20%20%20%20%20database,%20see%20www.loni.ucla.edu/ADNI%29.%20ADNI%20was%20launched%20in%202003%20by%20the%0A%20%20%20%20%20%20National%20Institute%20on%20Aging,%20the%20National%20Institute%20of%20Biomedical%20Imaging%0A%20%20%20%20%20%20and%20Bioengineering%20%28NIBIB%29,%20the%20Food%20and%20Drug%20Administration,%20private%0A%20%20%20%20%20%20pharmaceutical%20companies,%20and%20nonprofit%20organizations,%20as%20a%20$60%20million,%0A%20%20%20%20%20%205-year%20public-
private%20partnership.%20The%20primary%20goal%20of%20ADNI%20has%20been%20to%0A%20%20%20%20%20%20test%20whether%20serial%20magnetic%20resonance%20imaging%20%28MRI%29,%20PET,%20other%0A%20%20%20%20%20%20biological%20markers,%20and%20clinical%20and%20neuropsychological%20assessment%20can%20be%0A%20%20%20%20%20%20combined%20to%20measure%20the%20progression%20of%20MCI%20and%20early%20Alzheimer%27s%0A%20%20%20%20%20%20disease%20%28AD%29.%20The%20initial%20goal%20of%20ADNI%20was%20to%20recruit%20800%20adults,%20ages%2055%0A%20%20%20%20%20%20to%2090,%20to%20participate%20in%20the%20research%2014approximately%20200%20cognitively%20normal%0A%20%20%20%20%20%20older%20individuals%20to%20be%20followed%20for%203%20years,%20400%20people%20with%20MCI%20to%20be%0A%20%20%20%20%20%20followed%20for%203%20years,%20and%20200%20people%20with%20early%20AD%20to%20be%20followed%20for%202%0A%20%20%20%20%20%20years.%20For%20up-
to-date%20information,%20see%20www.adni-
info.org.%20The%20current%0A%20%20%20%20%20%20sample%20was%20restricted%20to%20those%20subjects%20who%20had%20either%20a%20PIB-
PET%0A%20%20%20%20%20%20assessment%20or%20a%20CSF-A%DF-1-42%20measurement.%20Within%20this%20subset,%20PIB-
PET%20was%0A%20%20%20%20%20%20available%20in%20103%20subjects%20including%2019%20HC,%2065%20MCI,%20and%2019%20AD%20subjects.%20The%0A%20%20%20%20%20%20CSF-A%DF-1-42%20concentration%20was%20assessed%20in%20a%20total%20of%20116%20HC,%20199%20MCI,%20and%0A%20%20%20%20%20%20102%20AD%20subjects%20%28see%20Fig.%201%20for%20further%20information%20on%20subjects%20and%20data%0A%20%20%20%20%20%20inclusion%29.%20Within%2055%20subjects,%20both%20CSF%20Ab1
--42%20and%20PIB-
PET%20were%0A%20%20%20%20%20%20assessed.%20The%20observation%20interval%20covered%202%20years,%20where%0A%20%20%20%20%20%20neuropsychological%20assessment,%20FDG-
PET%20scanning,%20and%20MRI%20acquisition%20was%0A%20%20%20%20%20%20conducted%20at%20baseline,%206,%2012,%20and%2024%20month.%20All%20collected%20data%20are%20freely%0A%20%20%20%20%20%20accessible%20online%20to%20researchers%20%28http://www.loni.ucla.edu/ADNI%29.%20General%0A%20%20%20%20%20%20inclusion%20criteria%20included%20an%20age%20between%2055%20and%2090%20years,%20a%20modified%0A%20%20%20%20%20%20Hachinski%20score%20%3D4,%20education%20of%20at%20least%206%20grade%20level,%20and%20stable%0A%20%20%20%20%20%20treatment%20of%20at%20least%204%20weeks%20in%20case%20of%20treatment%20with%20permitted%0A%20%20%20%20%20%20medication%20%28for%20full%20list,%20see%20http://www.adni-
info.org,%20Procedures%0A%20%20%20%20%20%20Manual%29.%20The%20diagnosis%20of%20AD%20was%20made%20according%20to%20the%20NINCDS-
ADRDA%0A%20%20%20%20%20%20criteria%20%28McKhann%20et%20al.%201984%29.%20Inclusion%20criteria%20for%20AD%20encompassed%0A%20%20%20%20%20%20subjective%20memory%20complaint,%20memory%20impairment%20as%20assessed%20by%20an%20education%0A%20%20%20%20%20%20adjusted%20score%20on%20delayed%20recall%20of%20a%20single%20paragraph%20recall%20from%20the%0A%20%20%20%20%20%20Wechsler%20Logical%20Memory%20II%20Subscale%20as%20follows:%200%20137%20years%20of%20education,%0A%20%20%20%20%20%20%3D2%3B%20for%208%201315%20years,%20%3D4%3B%20for%2016%20years%20or%20more,%20%3D8,%20a%20Mini%20Mental%20State%20Exam%0A%20%20%20%20%20%20%28MMSE%29%20score%20between%2020%20and%2026,%20and%20a%20clinical%20dementia%20rating%20%28CDR%29%20score%0A%20%20%20%20%20%20of%200.5%20or%201.%20For%20the%20diagnosis%20of%20amnestic%20MCI,%20the%20subjects%20had%20to%20show%0A%20%20%20%20%20%20subjective%20memory%20impairment%20and%20objective%20memory%20impairment%20identical%20to%0A%20%20%20%20%20%20that%20for%20AD,%20a%20CDR%20of%200.5%20including%20the%20memory%20box%20score%20of%200.5%20or%0A%20%20%20%20%20%20greater,%20and%20a%20MMSE%20score%20between%2024%20and%2030,%20with%20unimpaired%20general%0A%20%20%20%20%20%20cognitive%20ability%20and%20functional%20performance%20such%20that%20they%20did%20not%20meet%0A%20%20%20%20%20%20criteria%20for%20dementia.%20HC%20had%20to%20show%20normal%20performance%20on%20the%20Logical%0A%20%20%20%20%20%20Memory%20II%20Subscale%20adjusted%20for%20education%20as%20follows:%200%20137%20years,%20%3D3,%208%201315%0A%20%20%20%20%20%20years,%20%3D5%3B%2016%20or%20more%20years,%20%3D9,%20and%20absence%20of%20significant%20impairment%20on%0A%20%20%20%20%20%20cognitive%20function%20or%20activities%20of%20daily%20living%20%28Ewers%20et%20al.%202010%29.%20CSF%0A%20%20%20%20%20%20Measurement:%20All%20CSF%20samples%20collected%20at%20the%20different%20centers%20were%0A%20%20%20%20%20%20shipped%20on%20dry%20ice%20to%20the%20Penn%20ADNI%20Biomarker%20Core%20Laboratory%20at%20the%0A%20%20%20%20%20%20University%20of%20Pennsylvania,%20Philadelphia,%20for%20storage%20at%20-80%B0C%20until%0A%20%20%20%20%20%20further%20analysis%20at%20the%20laboratory.%20More%20details%20on%20data%20collection%20of%20the%0A%20%20%20%20%20%20CSF%20samples%20can%20be%20found%20at%20http://www.adni-
info.org,%20under%20%22ADNI%0A%20%20%20%20%20%20study%20procedures.%22%20The%20CSF%20concentration%20of%20A%DF-1-42,%20t-tau,%20and%0A%20%20%20%20%20%20p-tau181%20were%20measured%20in%20the%20baseline%20CSF%20samples%20using%20the%20multiplex%0A%20%20%20%20%20%20xMAP%20Luminex%20platform%20%28Lumnix%20Corp,%20Austin,%20TX%29%20at%20the%20Penn%20ADNI%20Biomarker%0A%20%20%20%20%20%20Core%20Laboratory.%20For%20detailed%20description,%20see%20Shaw%20et%20al.%20%282009%29.%0A%20%20%20%20%20%20PIB-
PET,%20FDG-
PET,%20MRI%20Acquisition,%20and%20ROI%20Measurement:%20All%20MRI%20data%20were%0A%20%20%20%20%20%20acquired%20on%201.5-T%20MRI%20scanners%20using%20a%20volumetric%20T1-weighted%20sequences%20to%0A%20%20%20%20%20%20map%20brain%20structures,%20optimized%20for%20the%20different%20scanners%20as%20indicated%20at%0A%20%20%20%20%20%20http://www.loni.ucla.edu/ADNI/Research/Cores/index%20%28Jack,%20Bernstein,%20et%0A%20%20%20%20%20%20al.%202008%29.%20Freesurfer%20software%20version%204.5%20%28Dale%20et%20al.%201999%3B%20Fischl%20et%0A%20%20%20%20%20%20al.%201999%29%20was%20employed%20to%20measure%20longitudinal%20changes%20in%20regional%20brain%0A%20%20%20%20%20%20volumes.%20Briefly,%20the%20image-
processing%20pipeline%20using%20FreeSurfer%20consisted%0A%20%20%20%20%20%20of%20five%20stages:%20an%20affine%20registration%20with%20Talairach%20space,%20an%20initial%0A%20%20%20%20%20%20volumetric%20labeling,%20bias%20field%20correction,%20nonlinear%20alignment%20to%20the%0A%20%20%20%20%20%20Talairach%20space,%20and%20a%20final%20labeling%20of%20the%20volume.%20The%20fully%20automated%0A%20%20%20%20%20%20labeling%20of%20volumes%20is%20achieved%20by%20warping%20a%20population%20based%20brain%20atlas%0A%20%20%20%20%20%20to%20the%20target%20brain%20and%20by%20maximizing%20an%20a%20posteriori%20probability%20of%20the%0A%20%20%20%20%20%20labels%20given%20specific%20constraints.%20A%20full%20description%20of%20the%20FreeSurfer%0A%20%20%20%20%20%20processing%20steps%20can%20be%20found%20in%20%28Fischl%20et%20al.%202002%29.%20The%20procedures%20have%0A%20%20%20%20%20%20been%20extensively%20validated.%20MRI-
volume%20ROIs%20were%20selected%20based%20on%20the%0A%20%20%20%20%20%20previous%20meta-
analyses%20on%20MRI%20gray%20matter%20volume%20measures%20that%20were%20most%0A%20%20%20%20%20%20predictive%20of%20AD,%20including%20the%20hippocampus,%20middle%20temporal%20gyrus,%0A%20%20%20%20%20%20superior%20temporal%20gyrus,%20amygdala,%20parahippocampus,%20entorhinal%20cortex,%0A%20%20%20%20%20%20inferior%20parietal%20lobe,%20precuneus,%20and%20thalamus%20%28Schroeter%20et%20al.%202009%29.%0A%20%20%20%20%20%20PET%20data%20were%20acquired%20on%20multiple%20instruments%20of%20varying%20resolution.%20PIB%0A%20%20%20%20%20%20scans%20were%20collected%20as%204%20%D7%205%20min%20frames%20beginning%2050%20min%20after%20injection%0A%20%20%20%20%20%20of%20tracer.%20FDG%20scans%20were%20collected%20as%206%20%D7%205%20min%20frames%20beginning%2030%20min%0A%20%20%20%20%20%20after%20injection%20of%20approximately%205%20mCi%20of%20tracer.%20Attenuation%20correction%0A%20%20%20%20%20%20was%20performed%20either%20via%20transmission%20scan%20or%20computer%20tomography.%20Images%0A%20%20%20%20%20%20were%20uploaded%20to%20the%20Laboratory%20of%20Neuroimaging%20where%20they%20were%20processed%0A%20%20%20%20%20%20to%20provide%20standard%20orientation,%20voxel%20size,%20and%20resolution.%20FDG-
PET%20ROIs%0A%20%20%20%20%20%20were%20constructed%20based%20on%20a%20meta-analysis%20of%20the%20location%20of%20FDG-
PET%0A%20%20%20%20%20%20changes%20in%20the%20brain%20that%20are%20typically%20affected%20in%20AD%20as%20described%0A%20%20%20%20%20%20previously%20%28Jagust%20et%20al.%202009%3B%20Landau%20et%20al.%202009%29.%20FDG%20uptake%20was%0A%20%20%20%20%20%20normalized%20to%20a%20reference%20region%20composed%20of%20the%20pons%20and%20cerebellum%20and%0A%20%20%20%20%20%20measured%20in%20the%20target%20ROIs%20that%20included%20bilateral%20angular%20gyrus,%0A%20%20%20%20%20%20posterior%20cingulate/precuneus,%20and%20inferior%20temporal%20cortex%20as%20described%0A%20%20%20%20%20%20previously%20%28Jagust%20et%20al.%202009%29.%20PIB-
PET%20uptake%20was%20normalized%20to%20the%0A%20%20%20%20%20%20cerebellum%20to%20generate%20maps%20of%20the%20PIB-
PET%20score%20used%20for%20further%0A%20%20%20%20%20%20statistical%20analysis.%20Target%20ROIs%20were%20drawn%20on%20a%20structural%20MRI%20template%0A%20%20%20%20%20%20from%20a%20single%2079-year-
old%20MCI%20subject%20scanned%20at%20the%20University%20of%0A%20%20%20%20%20%20Pittsburgh.%20This%20image%20was%20deemed%20an%20%22average%22%20older%20subject%0A%20%20%20%20%20%20with%20typical%20atrophy%20and%20ventricular%20size.%20Each%20subject%27s%20PIB-
PET%0A%20%20%20%20%20%20score%20map%20was%20coregistered%20to%20the%20individual%20MRI%20with%20SPM5%20that%20was%0A%20%20%20%20%20%20normalized%20to%20the%20MCI%20template%20with%20SPM5%20and%20permitted%20the%20transformation%0A%20%20%20%20%20%20of%20the%20subject%27s%20PIB-
PET%20to%20the%20template%20space.%20ROIs%20in%20which%20PIB%0A%20%20%20%20%20%20uptake%20is%20known%20to%20predominate%20were%20averaged%20in%20left%20and%20right%20hemispheres%0A%20%20%20%20%20%20and%20comprised%20of%20prefrontal,%20lateral%20temporal,%20anterior%20cingulate%20gyrus,%0A%20%20%20%20%20%20parietal%20and%20posterior%20cingulate/precuneus.%20Further%20information%20is%0A%20%20%20%20%20%20available%20at%20the%20ADNI%20webpage%20%28http://www.loni.ucla.edu/ADNI/%29.%0A%20%20%20%20%20%20Neuropsychological%20Tests:%20Global%20cognitive%20ability%20was%20assessed%20with%20the%0A%20%20%20%20%20%20neuropsychological%20test%20battery%20Alzheimer%27s%20Disease%20Assessment%0A%20%20%20%20%20%20Scale%2013cognitive%20section%20%28ADAS-
cog%29%20%28Rosen%20et%20al.%201984%29.%20The%20ADAS-
cog%20score%0A%20%20%20%20%20%20is%20the%20total%20score%20on%20a%20number%20of%20tests%20on%20learning%20and%20memory,%20language%0A%20%20%20%20%20%20production,%20language%20comprehension,%20constructional%20praxis,%20ideational%0A%20%20%20%20%20%20praxis,%20and%20orientation%20%28see%20ADNI%20procedures%20manual%20for%20details%20at%0A%20%20%20%20%20%20http://www.adni-
info.org/Scientists/ProceduresManuals.aspx%29.%20A%20higher%0A%20%20%20%20%20%20score%20on%20ADAS-
cog%20scores%20indicates%20lower%20cognitive%20performance.%20Episodic%0A%20%20%20%20%20%20memory%20was%20assessed%20with%20the%20Rey%20Auditory%20Verbal%20Learning%20Test%20%28RAVLT%29,%0A%20%20%20%20%20%20using%20the%20score%20on%20the%2030-min%20delayed%20recall%20of%20a%20list%20of%2015%20words%20that%0A%20%20%20%20%20%20had%20been%20repeatedly%20presented%20and%20recalled%20during%20the%20learning%20phase%20of%205%0A%20%20%20%20%20%20verbal%20presentations%20of%20the%20list%20%28Rey%201964%29.%20The%20test%20score%20corresponds%20to%0A%20%20%20%20%20%20the%20number%20of%20words%20recalled%20on%20the%2030-min%20delayed%20test.%20For%20details%20on%0A%20%20%20%20%20%20the%20administration%20and%20scoring,%20see%20the%20%22Procedures%20Manual%22%0A%20%20%20%20%20%20%28http://www.adni-
info.org/Scientists/ProceduresManuals.aspx%29.%0A%20%20%20%20</description>%0A%20%20</descriptions>%0A</resource> datacite.title
CSF%20Biomarker%20and%20PIB-PET%20Derived%20Beta-
Amyloid%20Signature%20Predicts%20Metabolic,%20Grey%20Matter%20and%20Cognitive%20Changes%20in%20Non-Demented%20Subjects.
mrt.creator ucsf_datashare datacite.creator
Ewers,%20Michael%3B%20Insel,%20Philip%3B%20Jagust,%20William%20J.%3B%20Shaw,%20Leslie%3B%20Trojanowski,%20John%20Q.%3B%20Aisen,%20Paul%3B%20Petersen,%20Ronald%20C.%3B%20Schuff,%20Norbert%3B%20Weiner,%20Michael%20W.
erc
who:%20Ewers,%20Michael%3B%20Insel,%20Philip%3B%20Jagust,%20William%20J.%3B%20Shaw,%20Leslie%3B%20Trojanowski,%20John%20Q.%3B%20Aisen,%20Paul%3B%20Petersen,%20Ronald%20C.%3B%20Schuff,%20Norbert%3B%20Weiner,%20Michael%20W.%0Awhat:%20CSF%20Biomarker%20and%20PIB-
PET%20Derived%20Beta-
Amyloid%20Signature%20Predicts%0A%20%20%20%20%20%20Metabolic,%20Grey%20Matter%20and%20Cognitive%20Changes%20in%20Non-
Demented%20Subjects%0Awhen:%202012%0Awhere:%20ark:/b7272/q6154f00%0Awhere:%20doi:10.7272/Q6154F00 datacite.publicationyear 2012
datacite.resourcetype Dataset